| Base Case Assumption | Sensitivity Analysis | Cost per QALY Gained |
| --- | --- | --- |
| Time horizon of 15 years | Time horizon extended to 20 years | £ 45281 |
| Observed treatment effects persist | Treatment effect no longer persists in extrapolation |  |
| to the end of the time horizon |  |  |
| Utilities: PFS = 0.8; progressed = 0.6 | Utilities: PFS = 0.9; progressed = 0.5 | £ 20307 |
| Utilities: PFS = 0.8; progressed = 0.6 | Utilities: PFS = 0.75; progressed = 0.65 | £ 52883 |
| Oral administration of FC | IV infusion of FC = actual dose from trial | £ 30904 |
| Oral administration of FC | IV infusion of FC = recommended dose | £ 33919 |
| Adverse event costs excluded | Inclusion of adverse event costs | £ 34501 |
|  | Monthly supportive care cost increase by 50% | £ 34453 |
|  | Monthly supportive care cost decrease by 50% | £ 34265 |
|  | Drug administration cost upper quartile | £ 37405 |
|  | Drug administration cost lower quartile | £ 31025 |
| FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; QALY, quality-adjusted life year. | | |